Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines
Figure 1
Effects of SMI on the BrdU incorporation of CRC cell lines. HROC18, HROC24, HROC43, and HROC46 cells growing in 96-well half-area microplates were treated with (a) vemurafenib, (b) trametinib (please note the logarithmic scale -axis), (c) perifosine, and (d) regorafenib as indicated for 24 h, before DNA synthesis was assessed with the BrdU incorporation assay. In (e), HROC24 cells were incubated with combinations of SMI as indicated. One hundred percent BrdU incorporation corresponds to cells cultured without SMI. Data are presented as mean SEM ( separate cultures); versus control cultures with Bonferroni-adjusted ; versus cultures treated with either of the two combined substances alone with Bonferroni-adjusted .
